Wiki-Pi

Search Results for: Cancer

23406 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BRCA2 and UQCC1 breast cancer 2, early onset ubiquinol-cytochrome c reductase complex assembly factor 1
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
BRCA2 and CDK2 breast cancer 2, early onset cyclin-dependent kinase 2
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Activation of the pre-replicative complex
  • Cellular Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • G2/M Transition
  • p53-Dependent G1/S DNA damage checkpoint
  • Activation of the pre-replicative complex
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • CDK-mediated phosphorylation and removal of Cdc6
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A/B1 associated events during G2/M transition
  • G2 Phase
  • Activation of ATR in response to replication stress
  • G1/S Transition
  • Removal of licensing factors from origins
  • Mitotic G1-G1/S phases
  • Switching of origins to a post-replicative state
  • G1/S DNA Damage Checkpoints
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • DNA Replication Pre-Initiation
  • M/G1 Transition
  • Regulation of DNA replication
  • Senescence-Associated Secretory Phenotype (SASP)
  • G0 and Early G1
  • S Phase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Factors involved in megakaryocyte development and platelet production
  • Cell Cycle, Mitotic
  • APC/C-mediated degradation of cell cycle proteins
  • SCF(Skp2)-mediated degradation of p27/p21
  • Orc1 removal from chromatin
  • Regulation of mitotic cell cycle
  • Cell Cycle Checkpoints
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Double Oxidized Cysteine
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Flavopiridol
  • (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • Alsterpaullone
  • N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide
  • N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE
  • (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL
  • (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
  • N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
  • 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
  • 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE
  • 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE
  • 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
  • N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
BRCA2 and PLK1 breast cancer 2, early onset polo-like kinase 1
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Phosphorylation of the APC/C
  • Mitotic Prometaphase
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Organelle biogenesis and maintenance
  • Mitotic Telophase/Cytokinesis
  • Separation of Sister Chromatids
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Nuclear Envelope Breakdown
  • G2/M Transition
  • Mitotic Metaphase/Anaphase Transition
  • Phosphorylation of Emi1
  • Mitotic Anaphase
  • Regulation of PLK1 Activity at G2/M Transition
  • M Phase
  • Cyclin A/B1 associated events during G2/M transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Assembly of the primary cilium
  • Regulation of APC/C activators between G1/S and early anaphase
  • Anchoring of the basal body to the plasma membrane
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Resolution of Sister Chromatid Cohesion
  • Regulation of mitotic cell cycle
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • Centrosome maturation
  • Condensation of Prophase Chromosomes
  • Mitotic G2-G2/M phases
  • Polo-like kinase mediated events
  • Mitotic Metaphase and Anaphase
BRCA2 and RPA1 breast cancer 2, early onset replication protein A1, 70kDa
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • HSF1 activation
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • G2/M Checkpoints
  • Repair synthesis for gap-filling by DNA polymerase in TC-NER
  • Activation of the pre-replicative complex
  • DNA strand elongation
  • Mismatch Repair
  • G1/S Transition
  • Homologous recombination repair of replication-independent double-strand breaks
  • Mitotic G1-G1/S phases
  • Removal of the Flap Intermediate from the C-strand
  • Chromosome Maintenance
  • DNA Replication Pre-Initiation
  • S Phase
  • Removal of the Flap Intermediate
  • Global Genomic NER (GG-NER)
  • Nucleotide Excision Repair
  • Activation of the pre-replicative complex
  • Extension of Telomeres
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Assembly of the RAD51-ssDNA nucleoprotein complex
  • Telomere Maintenance
  • Activation of ATR in response to replication stress
  • Processing of DNA double-strand break ends
  • Double-Strand Break Repair
  • Dual incision reaction in GG-NER
  • Meiotic recombination
  • Synthesis of DNA
  • Lagging Strand Synthesis
  • Processive synthesis on the C-strand of the telomere
  • Processive synthesis on the lagging strand
  • M/G1 Transition
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • Telomere C-strand (Lagging Strand) Synthesis
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Repair synthesis of patch ~27-30 bases long by DNA polymerase
  • Cell Cycle, Mitotic
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Homologous DNA pairing and strand exchange
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Transcription-coupled NER (TC-NER)
  • Homologous Recombination Repair
  • Formation of incision complex in GG-NER
  • Cell Cycle Checkpoints
BRCA2 and SERPINH1 breast cancer 2, early onset serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Collagen formation
  • Collagen biosynthesis and modifying enzymes
BRCA2 and CCNA2 breast cancer 2, early onset cyclin A2
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Cellular Senescence
  • G2/M Transition
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1 associated events during G2/M transition
  • G1/S Transition
  • G2 Phase
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • Regulation of DNA replication
  • G0 and Early G1
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Senescence-Associated Secretory Phenotype (SASP)
  • Regulation of APC/C activators between G1/S and early anaphase
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • Orc1 removal from chromatin
  • SCF(Skp2)-mediated degradation of p27/p21
  • Regulation of mitotic cell cycle
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic G2-G2/M phases
BRCA2 and HNRNPC breast cancer 2, early onset heterogeneous nuclear ribonucleoprotein C (C1/C2)
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Processing of Capped Intron-Containing Pre-mRNA
  • mRNA Splicing
  • mRNA Splicing - Major Pathway
BRCA2 and PALB2 breast cancer 2, early onset partner and localizer of BRCA2
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Fanconi Anemia pathway
BRCA2 and C11orf30 breast cancer 2, early onset chromosome 11 open reading frame 30
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
BRCA2 and STAT5A breast cancer 2, early onset signal transducer and activator of transcription 5A
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Signaling by PDGF
  • Signaling by FGFR in disease
  • Cytokine Signaling in Immune system
  • Signaling by ERBB4
  • Signaling by SCF-KIT
  • Signaling by Interleukins
  • Nuclear signaling by ERBB4
  • Downstream signal transduction
  • Signaling by FGFR1 mutants
  • Interleukin-7 signaling
  • Signaling by FGFR mutants
  • Interleukin-2 signaling
  • Prolactin receptor signaling
  • Signaling by FGFR1 fusion mutants
  • Interleukin-3, 5 and GM-CSF signaling
  • Signaling by Leptin
  • Growth hormone receptor signaling
BRCA2 and HMG20B breast cancer 2, early onset high mobility group 20B
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Chromatin modifying enzymes
  • Chromatin organization
  • HDACs deacetylate histones
  • Factors involved in megakaryocyte development and platelet production
BRCA2 and NEDD4 breast cancer 2, early onset neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase
  • Homologous DNA pairing and strand exchange
  • Meiotic recombination
  • Fanconi Anemia pathway
  • Homologous Recombination Repair
  • Homologous recombination repair of replication-independent double-strand breaks
  • Double-Strand Break Repair
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Downregulation of ERBB4 signaling
  • Antigen processing: Ubiquitination & Proteasome degradation
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Cytokine Signaling in Immune system
  • Class I MHC mediated antigen processing & presentation
  • Signaling by ERBB4
  • Antiviral mechanism by IFN-stimulated genes
  • Adaptive Immune System
BTC and EGFR betacellulin epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • GRB2 events in ERBB2 signaling
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nuclear signaling by ERBB4
  • SHC1 events in ERBB4 signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
BTC and ERBB2 betacellulin erb-b2 receptor tyrosine kinase 2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • GRB2 events in ERBB2 signaling
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nuclear signaling by ERBB4
  • SHC1 events in ERBB4 signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
C2 and PSMA4 complement component 2 proteasome (prosome, macropain) subunit, alpha type, 4
  • Regulation of Complement cascade
  • Complement cascade
  • Activation of C3 and C5
  • Initial triggering of complement
  • Innate Immune System
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • Hh ligand biogenesis disease
  • T41 mutants of beta-catenin aren't phosphorylated
  • Downstream signaling events of B Cell Receptor (BCR)
  • Degradation of beta-catenin by the destruction complex
  • Stabilization of p53
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • DNA Replication Pre-Initiation
  • S45 mutants of beta-catenin aren't phosphorylated
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • Autodegradation of the E3 ubiquitin ligase COP1
  • AMER1 mutants destabilize the destruction complex
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • PCP/CE pathway
  • Adaptive Immune System
  • CDK-mediated phosphorylation and removal of Cdc6
  • Hedgehog ligand biogenesis
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Separation of Sister Chromatids
  • HIV Infection
  • Ubiquitin-dependent degradation of Cyclin D
  • APC truncation mutants have impaired AXIN binding
  • Assembly of the pre-replicative complex
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • p53-Dependent G1 DNA Damage Response
  • S37 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • p53-Independent DNA Damage Response
  • p53-Independent G1/S DNA damage checkpoint
  • G1/S DNA Damage Checkpoints
  • Vpu mediated degradation of CD4
  • Synthesis of DNA
  • M/G1 Transition
  • Ubiquitin-dependent degradation of Cyclin D1
  • TCF dependent signaling in response to WNT
  • SCF-beta-TrCP mediated degradation of Emi1
  • degradation of AXIN
  • Signaling by Hedgehog
  • Regulation of mitotic cell cycle
  • Degradation of GLI1 by the proteasome
  • degradation of DVL
  • Cell Cycle Checkpoints
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Regulation of Apoptosis
  • Degradation of GLI2 by the proteasome
  • Signaling by the B Cell Receptor (BCR)
  • Vif-mediated degradation of APOBEC3G
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • p53-Dependent G1/S DNA damage checkpoint
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • APC/C:Cdc20 mediated degradation of Securin
  • AUF1 (hnRNP D0) destabilizes mRNA
  • CDK-mediated phosphorylation and removal of Cdc6
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • truncations of AMER1 destabilize the destruction complex
  • Processing-defective Hh variants abrogate ligand secretion
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • AXIN missense mutants destabilize the destruction complex
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic Metaphase and Anaphase
  • Regulation of ornithine decarboxylase (ODC)
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Orc1 removal from chromatin
  • Mitotic Anaphase
  • M Phase
  • APC truncation mutants are not K63 polyubiquitinated
  • Metabolism of amino acids and derivatives
  • Hedgehog 'on' state
  • Programmed Cell Death
  • Class I MHC mediated antigen processing & presentation
  • Regulation of DNA replication
  • Cell Cycle, Mitotic
  • beta-catenin independent WNT signaling
  • Orc1 removal from chromatin
  • Activation of NF-kappaB in B cells
  • Asymmetric localization of PCP proteins
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Antigen processing-Cross presentation
  • CDT1 association with the CDC6:ORC:origin complex
  • ER-Phagosome pathway
VPS51 and CDKN1A vacuolar protein sorting 51 homolog (S. cerevisiae) cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
CALM1 and CCND2 calmodulin 1 (phosphorylase kinase, delta) cyclin D2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Cyclin D associated events in G1
  • G1 Phase
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
CALM1 and KRAS calmodulin 1 (phosphorylase kinase, delta) Kirsten rat sarcoma viral oncogene homolog
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Signalling to RAS
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Adaptive Immune System
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • Activation of RAS in B cells
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Constitutive Signaling by EGFRvIII
CALM1 and CCNE1 calmodulin 1 (phosphorylase kinase, delta) cyclin E1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • E2F mediated regulation of DNA replication
  • DNA Damage/Telomere Stress Induced Senescence
  • Cellular Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • p53-Dependent G1/S DNA damage checkpoint
  • G0 and Early G1
  • S Phase
  • Cyclin E associated events during G1/S transition
  • Cell Cycle, Mitotic
  • p53-Dependent G1 DNA Damage Response
  • SCF(Skp2)-mediated degradation of p27/p21
  • G1/S Transition
  • G1/S-Specific Transcription
  • Cell Cycle Checkpoints
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic G1-G1/S phases
  • G1/S DNA Damage Checkpoints
CALM1 and EGFR calmodulin 1 (phosphorylase kinase, delta) epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib

Page 20 out of 1171 pages